Viral Arthritis Vaccine Market Report 2026

Viral Arthritis Vaccine Market Overview

• Viral Arthritis Vaccine market size has reached to $6.66 billion in 2025 • Expected to grow to $11.09 billion in 2030 at a compound annual growth rate (CAGR) of 10.8% • Growth Driver: Rising Mosquito-Borne Viral Infections Driving Growth Of The Market Due To Increasing Cases Of Chikungunya And Related Viruses And Expanding Vaccination Efforts • Market Trend: Advancement Of Live-Attenuated And Next-Generation Chikungunya Vaccines Strengthening Viral Arthritis Prevention • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Viral Arthritis Vaccine Market?

A viral arthritis vaccine refers to a preventive immunization designed to stimulate the immune system to produce protective antibodies and cellular immunity against viruses that can cause arthritis, such as Chikungunya virus, Ross River virus, and other arthritogenic viruses, thereby reducing the risk, severity, and long-term complications of virus-induced joint inflammation. It aims to prevent acute febrile illness and chronic inflammatory arthritis by blocking viral infection, limiting viral replication, and minimizing immune-mediated joint damage in exposed or high-risk populations. The main types of viral arthritis vaccine include viral arthritis vaccine, live, and viral arthritis vaccine, inactivated. Viral arthritis vaccine, live, refers to vaccines that use a weakened form of the virus to stimulate immunity against viral arthritis. These vaccines target viruses such as chikungunya virus, rubella virus, parvovirus, and other viral arthritis-causing viruses. They are applied across farms and individual use, and are administered to end users including hospitals and clinics, vaccination centers, homecare, and government programs.

What Is The Viral Arthritis Vaccine Market Growth Forecast?

The viral arthritis vaccine market size is expected to see rapid growth in the next few years. It will grow to $11.09 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to next generation vaccine platforms, emerging arbovirus threats, accelerated clinical trials, global travel related exposure, preventive immunization expansion. Major trends in the forecast period include mrna based viral arthritis vaccines, recombinant vector vaccine platforms, multivalent arthritogenic virus vaccines, rapid response vaccine design, adjuvanted immunogenic formulations.

Global Viral Arthritis Vaccine Market Segmentation

1) By Type: Viral Arthritis Vaccine, Live; Viral Arthritis Vaccine, Inactivated 2) By Virus Targeted: Chikungunya Virus; Rubella Virus; Parvovirus; Other Viral Arthritis-Causing Viruses 3) By Application: Farms; Individual 4) By End-User: Hospitals And Clinics; Vaccination Centers; Homecare; Government Programs Subsegments: 1) By Viral Arthritis Vaccine, Live: Single Dose; Combination Dose; Recombinant Live Vaccine 2) By Viral Arthritis Vaccine, Inactivated: Whole Virus Inactivated Vaccine; Split Virus Inactivated Vaccine; Adjuvanted Inactivated Vaccine

What Is The Driver Of The Viral Arthritis Vaccine Market?

A rising incidence of mosquito-borne viral infections is expected to propel the growth of the viral arthritis vaccine market going forward. Mosquito-borne viral infections refer to diseases transmitted to humans through the bite of infected mosquitoes, including chikungunya, Zika, and dengue viruses, which can cause symptoms such as fever, joint pain, rash, and, in some cases, long-term complications like viral arthritis. Mosquito-borne viral infections are increasing due to climate change creating warmer temperatures and altered rainfall patterns that expand mosquito habitats and breeding seasons. A viral arthritis vaccine helps reduce mosquito-borne viral infections by preventing infection and disease progression from viruses that cause joint inflammation, thereby lowering transmission risk and disease burden in affected populations. For instance, in 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 7.6 million cases were reported globally by April, tripling the number recorded during the same period in 2023, with transmission continuing to spread across more than 90 countries. Therefore, the rising incidence of mosquito-borne viral infections is driving growth of the viral arthritis vaccine industry.

Key Players In The Global Viral Arthritis Vaccine Market

Major companies operating in the viral arthritis vaccine market are Bavarian Nordic A/S, Serum Institute of India Private Limited, Valneva SE, Bharat Biotech International Limited, Panacea Biotec Ltd., The Biologicals and Vaccines Institute of Southern Africa (Pty) Ltd.

Global Viral Arthritis Vaccine Market Trends and Insights

Major companies operating in the viral arthritis vaccine market are focusing on advancing innovative vaccine candidates, such as live-attenuated and next-generation chikungunya vaccines, to address the growing need for effective prevention of viral-induced joint pain and long-term arthritic complications, particularly in vulnerable populations. Live-attenuated and next-generation chikungunya vaccines refer to advanced vaccine formulations designed to prevent chikungunya virus infection by eliciting strong and long-lasting immune responses, where live-attenuated vaccines use weakened forms of the virus to closely mimic natural infection and provide durable protection, and next-generation vaccines employ modern platforms such as viral vectors, recombinant proteins, or novel attenuation technologies to enhance safety, immunogenicity, and broader population applicability. For instance, in June 2025, Bavarian Nordic A/S, a Denmark-based biotechnology company, initiated a Phase 3 clinical study of its chikungunya vaccine in children, aiming to expand protection to pediatric populations in endemic regions, where early-life exposure can lead to significant disease burden. The progression to late-stage clinical evaluation reflects growing confidence in the vaccine’s safety and immunogenicity profile and underscores efforts to broaden age indications, strengthen population-level immunity, and reduce the long-term impact of chikungunya-associated viral arthritis globally.

What Are Latest Mergers And Acquisitions In The Viral Arthritis Vaccine Market?

In December 2024, Valneva SE, a France-based biotech company, partnered with the Serum Institute of India for its single-shot chikungunya vaccine under an exclusive licensing agreement. With this collaboration, the partners aimed to expand access to the vaccine across Asia and support broader supply to low- and middle-income countries, leveraging local manufacturing and regulatory capabilities. The Serum Institute of India is an India-based company that specializes in producing and distributing affordable vaccines at large scale to public health markets worldwide.

Regional Insights

North America was the largest region in the viral arthritis vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Viral Arthritis Vaccine Market?

The viral arthritis vaccine market consists of sales of live-attenuated viral vaccines, inactivated viral vaccines, virus-like particle-based vaccines, recombinant subunit vaccines, messenger ribonucleic acid-based vaccines, and viral vector-based vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Viral Arthritis Vaccine Market Report 2026?

The viral arthritis vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the viral arthritis vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.